Market Closed -
OTC Markets
01:18:57 25/05/2024 am IST
|
5-day change
|
1st Jan Change
|
2.11
USD
|
-8.26%
|
|
0.00%
|
-63.26%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Capitalization
1 |
5.363
|
19.27
|
24.02
|
8.254
|
2.867
|
1.356
|
-
|
Enterprise Value (EV)
1 |
5.363
|
19.27
|
24.02
|
8.254
|
2.867
|
1.356
|
1.356
|
P/E ratio
|
-0.19
x
|
-1.34
x
|
-2.11
x
|
-0.6
x
|
-0.13
x
|
-0.2
x
|
-0.18
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
6.65
x
|
24.1
x
|
39.1
x
|
18.3
x
|
47.8
x
|
1.13
x
|
0.52
x
|
EV / Revenue
|
6.65
x
|
24.1
x
|
39.1
x
|
18.3
x
|
47.8
x
|
1.13
x
|
0.52
x
|
EV / EBITDA
|
-0.64
x
|
-2.04
x
|
-2.09
x
|
-0.63
x
|
-0.2
x
|
-0.15
x
|
-0.12
x
|
EV / FCF
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
32.6
|
139
|
203
|
206
|
499
|
642.5
|
-
|
Reference price
2 |
164.6
|
138.7
|
118.1
|
40.07
|
5.743
|
2.110
|
2.110
|
Announcement Date
|
19/03/20
|
16/03/21
|
09/03/22
|
14/03/23
|
01/04/24
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net sales
1 |
0.806
|
0.799
|
0.614
|
0.45
|
0.06
|
1.2
|
2.6
|
EBITDA
1 |
-8.393
|
-9.427
|
-11.47
|
-13.19
|
-14.13
|
-9.134
|
-11.31
|
EBIT
1 |
-8.596
|
-9.609
|
-11.69
|
-13.45
|
-14.42
|
-9.398
|
-11.59
|
Operating Margin
|
-1,066.5%
|
-1,202.63%
|
-1,904.23%
|
-2,989.11%
|
-24,028.33%
|
-783.17%
|
-445.79%
|
Earnings before Tax (EBT)
1 |
-13.21
|
-10.15
|
-11
|
-13.41
|
-14.46
|
-13.5
|
-13.25
|
Net income
1 |
-12.96
|
-10.21
|
-11.03
|
-13.57
|
-14.46
|
-9.526
|
-11.62
|
Net margin
|
-1,607.44%
|
-1,277.35%
|
-1,796.58%
|
-3,014.67%
|
-24,091.67%
|
-793.83%
|
-446.94%
|
EPS
2 |
-852.0
|
-103.2
|
-55.92
|
-66.24
|
-43.68
|
-10.78
|
-11.58
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
19/03/20
|
16/03/21
|
09/03/22
|
14/03/23
|
01/04/24
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
0.152
|
0.149
|
0.103
|
0.111
|
0.087
|
0.06
|
-
|
-
|
-
|
0.3
|
0.3
|
0.3
|
0.3
|
-
|
-
|
EBITDA
1 |
-2.913
|
-3.262
|
-3.367
|
-3.421
|
-3.138
|
-3.731
|
-3.591
|
-3.631
|
-3.174
|
-2.406
|
-2.285
|
-2.241
|
-2.235
|
-
|
-
|
EBIT
1 |
-2.968
|
-3.321
|
-3.436
|
-3.49
|
-3.204
|
-3.8
|
-3.667
|
-3.703
|
-3.247
|
-2.44
|
-2.351
|
-2.307
|
-2.301
|
-
|
-
|
Operating Margin
|
-1,952.63%
|
-2,228.86%
|
-3,335.92%
|
-3,144.14%
|
-3,682.76%
|
-6,333.33%
|
-
|
-
|
-
|
-813.33%
|
-783.67%
|
-769%
|
-767%
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-2.969
|
-3.322
|
-3.434
|
-3.48
|
-3.174
|
-3.782
|
-3.681
|
-3.726
|
-3.266
|
-2.472
|
-3.5
|
-4
|
-4
|
-
|
-
|
Net income
1 |
-2.98
|
-3.331
|
-3.443
|
-3.489
|
-3.303
|
-3.782
|
-3.681
|
-3.726
|
-3.266
|
-2.472
|
-2.383
|
-2.339
|
-2.333
|
-
|
-
|
Net margin
|
-1,960.53%
|
-2,235.57%
|
-3,342.72%
|
-3,143.24%
|
-3,796.55%
|
-6,303.33%
|
-
|
-
|
-
|
-824%
|
-794.33%
|
-779.67%
|
-777.67%
|
-
|
-
|
EPS
2 |
-14.64
|
-16.32
|
-16.80
|
-17.04
|
-16.08
|
-18.24
|
-15.36
|
-9.840
|
-2.880
|
-4.770
|
-3.960
|
-1.030
|
-1.020
|
-6.240
|
-6.240
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
09/03/22
|
11/05/22
|
10/08/22
|
14/11/22
|
14/03/23
|
10/05/23
|
14/08/23
|
14/11/23
|
01/04/24
|
15/05/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
0.06
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
7.57%
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
19/03/20
|
16/03/21
|
09/03/22
|
14/03/23
|
01/04/24
|
-
|
-
|
Last Close Price
2.11
USD Average target price
12
USD Spread / Average Target +468.72% Consensus |
1st Jan change
|
Capi.
|
---|
| -63.26% | 1.36M | | +67.53% | 63.85B | | -0.77% | 41.83B | | +45.66% | 40.65B | | -10.72% | 27.12B | | +13.30% | 26.52B | | -22.79% | 18.69B | | +4.70% | 12.73B | | +24.10% | 12.11B | | +27.41% | 12.07B |
Other Biotechnology & Medical Research
|